Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

Rini, Brian I.; Powles, Thomas; Atkins, Michael B.; Escudier, Bernard; McDermott, David F.; Suarez, Cristina; Bracarda, Sergio; Stadler, Walter M.; Donskov, Frede; Lee, Jae Lyun; Hawkins, Robert; Ravaud, Alain; Alekseev, Boris; Staehler, Michael; Uemura, Motohide; De Giorgi, Ugo; Mellado, Begona; Porta, Camillo; Melichar, Bohuslav; Gurney, Howard; Bedke, Jens; Choueiri, Toni K.; Parnis, Francis; Khaznadar, Tarik; Thobhani, Alpa; Li, Shi; Piault-Louis, Elisabeth; Frantz, Gretchen; Huseni, Mahrukh; Schiff, Christina; Green, Marjorie C.; Motzer, Robert J.

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

Autor(en):

Rini, Brian I.; Powles, Thomas; Atkins, Michael B.; Escudier, Bernard; McDermott, David F.; Suarez, Cristina; Bracarda, Sergio; Stadler, Walter M.; Donskov, Frede; Lee, Jae Lyun; Hawkins, Robert; Ravaud, Alain; Alekseev, Boris; Staehler, Michael; Uemura, Motohide; De Giorgi, Ugo; Mellado, Begona; Porta, Camillo; Melichar, Bohuslav; Gurney, Howard; Bedke, Jens; Choueiri, Toni K.; Parnis, Francis; Khaznadar, Tarik; Thobhani, Alpa; Li, Shi; Piault-Louis, Elisabeth; Frantz, Gretchen; Huseni, Mahrukh; Schiff, Christina; Green, Marjorie C.; Motzer, Robert J.

Tübinger Autor(en):

Bedke, Jens

Erschienen in:

Lancet (2019), Bd. 393, H. 10189, S. 2404-2415

Verlagsangabe:

Elsevier Science Inc

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1016/S0140-6736(19)30723-8

ISSN:

1474-547X